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Advanced portal hypertension accompanying end-stage liver disease results in an altered milieu due to inadequate detoxiﬁcation
of blood from splanchnic circulation by the failing liver. The portosystemic shunts with hepatic dysfunction result in an
increased absorption and impaired neutralisation of the gastrointestinal bacteria and endotoxins leads to altered homeostasis
with multiorgan dysfunction. The important cardiopulmonary complications are cirrhotic cardiomyopathy, hepatopulmonary
syndrome, portopulmonary hypertension, and right-sided hydrothorax.
1. CirrhoticCardiomyopathy
Cardiovascular abnormalities have been reported by sev-
eral investigators. Systemic hemodynamic changes occur
in cirrhotic patients. There is hyperdynamic circulatory
state, decreased arterial blood pressure, decreased peripheral
resistance, and increased cardiac output [1]. Because of
reduced systemic vascular resistance and increased arterial
compliance, left ventricular failure may be latent in cirrhosis.
Impaired ventricular function become manifest under strain
or treatment with vasoconstrictors. This type of cardiac
dysfunction has been termed as cirrhotic cardiomyopathy.
Three major pathophysiologic abnormalities are
observed: cardiac electrophysiological abnormalities,
structural and functional ventricular abnormalities, and
abnormalventricularresponseinpresenceofpharmacologic,
physiologic, or surgical stress.
Cirrhotic patients have hyperdynamic circulation with
decreased peripheral vascular resistance, increased cardiac
output and stroke volume, increased organ blood ﬂow,
low systemic arterial pressure, and decreased arteriove-
nous oxygen diﬀerence. The level of circulating vasoactive
substances which are not inactivated by liver is increased
such as vasoactive intestinal peptide, glucagon, tumour
necrosis factor-α, prostacyclin, nitric oxide, endothelin-1,
and endothelin-3 [2].
The impaired ventricular response to stress and exercise
is due to impaired beta adrenergic signalling pathways,
cardiomyocyte dysfunction because of NO overproduc-
tion, increased endocannabinoids and carbon mono-oxide,
and/or decreased sensitivity to vasoconstrictors (endothelin-
1). Increased cell membrane ﬂuidity with beta-receptor
dysfunctioning occurs. Endocannabinoids act through CB1
receptors and result in arterial hypotension. CB1 receptor
stimulation also enhances the apoptosis of hepatic stellate
cells thus producing portal hypertension. Cardiac dysfunc-
tionduetolocalendocannabinoidsalsooccurs[3].Increased
NO production that occurs in cirrhosis decreases vascular
responsiveness to vasoconstrictors. NO antagonism can lead
to improved responsiveness to vasoconstrictors. There is
impaired function of membrane L-type calcium channels.
The intracellular storage and release of calcium is not
aﬀected.
There is decreased ventricular systolic response to stress.
Cardiac response to exercise is blunted. On stress testing,
cirrhotic patients have impaired increase in ejection fraction,
chronotropic incompetence, and decreased cardiac index.
Impaired cardiac performance occurs in alcoholic and non-
alcoholic cirrhotic patients; severity of disturbance depends
on degree of hepatic failure [4]. Patients primarily have
diastolic dysfunction with left ventricular hypertrophy, left2 International Journal of Hepatology
atrial enlargement, isovolumetric relaxation time prolonga-
tion, and decreased early to late diastolic ﬂow ratio (E/A
ratio). Systolic function of heart is related to heart rate,
stroke volume, and cardiac output. During exercise left
ventricular dimensions increase because of impaired cardiac
systolicfunction.Therightventricularandpulmonaryartery
p r e s s u r e ,a sw e l la sp u l m o n a r yc a p i l l a r yw e d g ep r e s s u r e
(PCWP) range around upper limit of normal [5].
Pathologically, in cirrhotic patients heart weight is
increased, dilatation of cardiac chambers, myocardial hyper-
trophy ,andstructuralchangessuchasmyocardialcelledema,
nuclear vacuolation, ﬁbrosis, exudates, and pigmentation
occur. The ventricular contractility is regulated by beta
adrenergic receptor signalling pathway. The activation of
receptor acts through stimulatory G protein (Gsa) with
increased cyclic AMP. The cyclic AMP promotes phos-
phorylation and activation of various cellular proteins by
stimulation of protein kinase, with increased intracellular
calcium and positive inotropic response [6].
The myocardial contractility is regulated by intracellular
calcium availability. ATP pumps transfer calcium from
cytoplasm into the sarcoplasmic reticulum (SR), the release
of calcium from sarcoplasmic reticulum is regulated by
calcium channels. Inﬂux of calcium through L-type calcium
channels of cell membrane stimulates further release of
calcium from the SR. Abnormal functioning of these L-type
calcium channels with resultant abnormal release of calcium
may explain the abnormality of myocardial contraction in
cirrhotic patients [7].
Due to altered lipid metabolism in cirrhosis, the choles-
terol content of membrane is increased with increased mem-
brane ﬂuidity resulting in desensitization of beta adrenergic
receptors. There is decreased Gsa levels in the membrane
andincreasedcatecholamineslevelsincirrhoticpatients.The
myocardial performance improves in cirrhotic patients after
administration of NO-synthetase inhibitor [8].
The increased level of nitric oxide attenuates the
activation of L-type of calcium channels. Nitric oxide
is produced by NO-synthetase from L-arginine. There is
transient bacteremia and increased levels of cytokines and
endotoxins, which stimulate the enzyme NO synthetase [9].
Nitric oxide has inhibitory eﬀect on myocardial contractility
through increased cGMP. Increased cyclic GMP impair beta
adrenergic receptor signalling and calcium release from
SR. There is transient bacteremia and endotoxin release in
cirrhotic patients with overproduction of cytokines. Carbon
monoxide levels are increased in cirrhotic patients. CO
induces guanylyl cyclase activity with increased cyclic GMP.
Inhibition of heme oxygenase activity can result in improved
myocardial contractility [10].
ThereisincreasedincorrectedQTinterval.Theincreased
interval correlates with a higher incidence of sudden cardiac
death [11]. The pathogenesis of increased QT interval is
unclear. The structural changes in cardiomyocyte membrane
with increased cholesterol content with resultant mem-
brane ﬂuidity that compromises the calcium and potassium
pumps. In cirrhotics increased plasma levels of estrogens
has also been implicated for the increased incidence of QT
interval prolongation. This interval is increased in 30 to 60%
of patients and level of increase relates to degree of hepatic
dysfunction. It is also increased in persons with mild portal
hypertension thus portosystemic shunting is related to the
increase in QTc interval. Increased interval improves with
liver transplantation [12].
Cirrhotic cardiomyopathy [CCM] remains clinically
undetectable but manifests under stressful stimuli. Cirrhotic
patients have peripheral vasodilatation thus reduced after-
load that prevents development of congestive heart failure.
Cardiac dysfunction may become manifest during stressful
conditions. Clinical interventions in cirrhotic patients such
as during TIPS placement may result in appearance of signs
of frank congestive heart failure.
The patients undergoing liver transplantation may
develop pulmonary edema because of cardiac dysfunction
together with volume replacement. Thus post transplant
patient must have careful ﬂuid replacement because of
reduced cardiac reserve. Another complication seen in these
post transplant patients is post perfusion syndrome, charac-
terised by decrease of mean arterial pressure of at least 30%
for1minutewithin5minutesafterreperfusionwithdecrease
of heart rate. Likely etiology of which is hyperkalemia,
acidosis, and increased tumour necrosis factor-α.
There are no clinical, imaging, or biochemical ﬁndings
that predict development of CCM so no precise diagnostic
criteria has been put forward. As there is no deﬁnite
diagnostic criteria for CCM treatment guidelines for man-
agement have not been clear. Because of the vasodilatation in
cirrhotic patients afterload is reduced so cardiac dysfunction
remains subtle. In patients with clinically evident heart
failure measures include bed rest, supplemental oxygen, and
careful use of diuretics.
The cirrhotic patients have reduced afterload so their tol-
erability to drugs that decrease preload/afterload is reduced.
There is beta receptor signalling defect because of reduced
densityofreceptorsincardiomyocytemembrane.Useofbeta
agonistssuchasdobutamineandisoproterenolislesslikelyto
be of beneﬁt. There is increased sympathetic catecholamine
stimulation in noncirrhotic heart failure. Thus, the use
of beta adrenoreceptor antagonists is preferred over beta
agonists in treating noncirrhotic patients with heart failure.
Use of aldosterone antagonists such as aldosterone results
in ventricular remodelling with reduced left ventricular
chamber size and thickness. There is also an improvement in
diastolic function with aldosterone antagonists. Orthotopic
liver transplantation has been associated with the gradual
improvement of the cardiac function over a period of 6 to
12 months. Thus cirrhotic cardiomyopathy represents one of
the complication of cirrhosis that can be reversed with the
liver transplantation [13].
2. Hepatopulmonary Syndrome
This terminology ﬁrst described in 1977 by Kennedy and
Knudson, is deﬁned by classical triad of presence of chronic
liver disease or portal hypertension, alteration of arterial
oxygenation, deﬁned as widened age corrected alveolar-
arterial oxygen gradient with or without arterial hypoxemiaInternational Journal of Hepatology 3
and evidence of intrapulmonary vascular dilatations [IPVD]
[14].
IPVD includes a variety of pulmonary vascular alteration
with resultant altered gas exchange due to diﬀuse peripheral
dilatation of pulmonary capillaries. The prevalence of HPS is
approximately 10 to 20% in cirrhotic patients evaluated for
liver transplant. Patients with cirrhosis should be evaluated
for HPS irrespective to the stage of the liver injury. The
median survival for HPS without liver transplant is 2 years.
T h es u r v i v a li sw o r s ei fP O 2 is less than 50mmHg, however
death is more so due to the complications of liver disease
or portal hypertension-related events rather than hypoxemic
respiratory failure [15, 16].
In HPS nearly 20% or more of the cardiac output
bypasses the functioning alveoli. With exercise this shunt
fraction increases. Patients with HPS mostly present with
dyspnoea on exertion and subsequently at rest. Most
patients will present with the signs and symptoms of
liver disease, including gastrointestinal bleeding, esophageal
varices, ascites, palmar erythema, and splenomegaly. Digital
clubbing, cyanosis, dyspnea, platypnea, and orthodeoxia are
the associated other pulmonary signs. Krowka et al. found
dyspnea to be the presenting symptom in 18% of patients
[17]. Platypnea, deﬁned as dyspnea induced by the upright
position and relieved by recumbency [18] and orthodeoxia,
deﬁned as arterial deoxygenation accentuated in the upright
position and relieved by recumbency [19]. Five percent of
patientsofcirrhosishaveplatypneaandorthodeoxia[20,21].
The main cause for severe hypoxemia related to HPS
is IPVD. Number of mechanisms have been described
in literature. The major mediator of pulmonary vascular
abnormality is nitric oxide (NO) a vasodilator molecule
guanylyl cyclase in vascular smooth muscle [22, 23]. There
is failure of the diseased liver to clear the pulmonary
vasodilators. Pulmonary vascular dilatation which results in
intrapulmonary shunting is the main determining factor
of an impaired gas exchange in HPS and can develop
in absence of ascites. There is dilatation of pulmonary
precapillary and capillary vessels and there is an alveolar
capillarydisequilibiriumordiﬀusion-perfusionimpairment.
The increased diameter of the capillary results in inability
of oxygen molecules in adjacent alveoli to diﬀuse in dilated
vessels resulting in impairment of oxygen uptake by RBCs in
the central stream of blood vessels [24].
There is also hyperdynamic circulation in the patients
with liver disease and there is shortened transit time to the
lung vasculature. Bacterial translocation in cirrhosis leads
to increased TNF-a, which leads to increased macrophage
adherence to pulmonary microvasculature with increased
inducible NO-synthase-derived NO production [25]. HPS
is not associated with any speciﬁc etiology of liver disease
and degree of hepatic dysfunction. It should be considered
independently of stage of liver disease. HPS has also been
diagnosed in noncirrhotic portal hypertension and in liver
diseases where portal hypertension is not a feature, such as
chronic viral hepatitis without cirrhosis. In patients who do
not undergo liver transplantation, the 5-year survival rate
is diminished in those who have HPS (20% versus 32–63%
without HPS) [26].
3.Diagnosis
Several screening algorithms have been proposed. One
simple and useful approach is by using pulse oximetry.
Oxygen saturation <96% has a sensitivity of 100% and
speciﬁcity of 88% to detect PaO2 < 70mmHg and may be
used to guide further workup for HPS [27].
In the evaluation of the hypoxemic cirrhotic patient
the exclusion of other contributing cardiopulmonary causes
such as pulmonary atelectasis, ascites, chronic obstructive
pulmonary disease, and hepatic hydrothorax is mandatory.
Chestradiographyshowsprominentpulmonaryvascular
markings in bilateral lower lobes, but ﬁnding is not speciﬁc.
However, a chest X-ray must still be taken to rule out
reversible conditions. Similarly, pulmonary function test
should be performed to rule out the common intrinsic
pulmonary disorders such as chronic obstructive pulmonary
disease.
Contrast echocardiography is the most sensitive test
to demonstrate intrapulmonary shunting [28]. It is done
usingintravenousinjectionsofagitatedsalineorindocyanine
green to produced bubbles of at least 15 microns in diameter.
Normally these microbubbles are trapped in the pulmonary
vasculatureandabsorbed.Inintracardiac righttoleftshunts,
these microbubbles are seen in the left heart within the ﬁrst
three cardiac cycles [29]. In hepatopulmonary syndrome,
because of intrapulmonary shunting, the bubbles are seen
in the left heart after the third heart beat, usually between
the third and sixth heart beat. Studies have shown that
transesophageal echocardiography is more sensitive than
transthoracic echocardiography in demonstrating intrapul-
monary shunting [30].
There are certain indirect evidences of HPS on echocar-
diography. A left atrial volume >50mL is a simple and
reliable parameter to detect HPS [31]. Right ventricular
diastolic dysfunction is more common in cirrhotic patients
with HPS than cirrhotic patients without HPS [32].
There are however a number of limitations of contrast-
enhanced echocardiography. It cannot quantify the shunt-
ing. It cannot diﬀerentiate between intrapulmonary vas-
cular dilatation and direct arteriovenous communication.
Although contrast echocardiography is highly sensitive for
HPS, it lacks speciﬁcity [33]. In patients with concomitant
intrinsic lung diseases, contrast echocardiography is a less
useful investigation to detect HPS.
To overcome the disadvantages of low speciﬁcity of con-
trast echocardiography, 99mTechnetium macroaggregated
albumin (Tc-99m MAA) lung perfusion scan is used. Albu-
min macroaggregates with more than 20μm in diameter,
normally are entrapped in the pulmonary vasculature.
In patients with intrapulmonary shunts, these albumin
macroaggregatesescapefromthepulmonaryvasculatureand
are taken up by other organs. Normally, less than 5% of
isotope reaches brain circulation compared to the lung. In
HPS patients, the fraction is more than 6% [34].
In cirrhotic patients with concomitant intrinsic pul-
monary disorders, Tc-99m MAA scan can diagnose HPS.
However, the major disadvantage of Tc-99m MAA scan is its
inability to diﬀerentiate intracardiac from intrapulmonary4 International Journal of Hepatology
shunting. Pulmonary angiography is another diagnostic
modality with potential usefulness [35].
It is however an invasive procedure. Hence, it is reserved
for those patients who have a poor response to 100% oxygen,
that is, increase in the PaO2 to less than 300mmHg. Two
angiographic patterns have been described. type 1 HPS is
characterized by precapillary pulmonary artery dilatation
without arteriovenous ﬁstulas. In type 2 HPS there is local-
ized pulmonary arteriovenous ﬁstulous communications.
type1angiographicﬁndingscanvaryfromnormaltodiﬀuse,
spider-like, or spongy appearance. type 1 HPS patients with
diﬀu s ep u l m o n a ryc h a n g e sh a v em o r es e v e r eh y p o x e m i aa n d
respondpoorlyto100%oxygen.Type2HPSislesscommon.
Patients with type 2 HPS do not respond to 100% oxygen.
These patients should be considered for embolotherapy
although there are case reports of coil embolization in
patients with type 1 HPS also.
Two newer diagnostic modalities for assessing HPS are
high-resolution chest computerized tomography (CT) and
evaluation of pulmonary blood transit time. The degree of
pulmonary microvascular dilation observed on chest CT
shows good correlation with the severity of gas exchange
abnormalities in patients with HPS. It also helps in quantiﬁ-
cation of intrapulmonary vasodilatation [36].
Recently, pulmonary transit time of erythrocytes, by
using echocardiographic analysis of human serum albumin
airmicrobubblecomplexes,alsocorrelatedwithgasexchange
abnormalities in a small group of patients with HPS [37].
These two modalities should be tested further in large-scale
studies to explore their potential in diagnosis of HPS.
4. Therapy
The only established eﬀective therapy for HPS is liver
transplantation. There is signiﬁcant improvement in gas
exchange postoperatively in more than 85% of reported
patients. However, it may take more than one year for the
gas exchange abnormalities to normalise [38].
There is increased mortality after transplantation in
patients who have HPS compared with subjects who do
not have HPS. Speciﬁcally patients with marked hypoxemia
(PaO2 < 50mmHg) and intrapulmonary shunting (shunt
fraction > 20%) have increased mortality. Interestingly,
unique complications such as pulmonary hypertension,
cerebral embolic hemorrhages, and immediate postoperative
deoxygenation requiring prolonged mechanical ventilation
may contribute to increased postoperative mortality and
morbidity [39–42].
Because of the complex relationship between hypoxia
secondary to HPS and liver transplantation, MELD excep-
tions points have been given to patients with HPS and a
resting PaO2 of <60mmHg by the UNOS. Oxygen supple-
mentation, although not studied in the treatment of HPS, is
commonly used when PaO2 < 60mmHg or in conditions
with exercise-induced oxygen desaturation. There are anec-
dotal reports supporting its use demonstrating enhancement
of arterial oxygenation, improvement in exercise tolerance,
and quality of life. Thus oxygen supplementation is a low-
risk treatment option [43].
A number of medical agents have been tried without
any robust data showing their beneﬁts. Small uncontrolled
studies have shown lack of eﬃcacy using sympathomimetic
agents, somatostatin, almitrine, indomethacin, and plasma
exchange [44]. An open label trial using garlic also suggests
ab e n e ﬁ c i a le ﬀect. In this trial, garlic powder was admin-
istered for a minimum of 6 months. Six out of 15 (40%)
patients with HPS demonstrated improvements greater than
10mmHg in the PaO2, and one had even resolution of
hypoxemia (PaO2: 46–80mmHg) over a 1.5-year period
[45].
Methylene blue infusion, a dye that inhibits the eﬀect
of NO on soluble guanylate cyclase, has also shown a
transient improvement in oxygenation. Inhaled L-NAME
which inhibits nitric oxide production, also transiently has
improved oxygenation in one patient (PaO2: 52–70mmHg),
but failed in another group of 10 patients [46]. There is a
single case report suggesting that norﬂoxacin also may be
beneﬁcial in improving oxygen saturation in HPS [47].
Af e wc a s er e p o r t sh a v ed o c u m e n t e dv a r i a b l ei m p r o v e -
ments in gas exchange using transjugular intrahepatic por-
tosystemicshunts(TIPSs).Inamorerecentstudyinvolving3
patients with HPS the use of TIPS did not lead to any overall
improvement and hence TIPS speciﬁcally to treat HPS is not
recommended [48].
However, there are reports of success of transcatheter
coil embolization of the arteriovenous pulmonary ﬁstulas
in type 2 HPS before and after liver transplantation [49].
Embolotherapymaythusbeareasonableﬁrst-lineoptionfor
bridging patients with Type 2 HPS prior to transplantation.
Even in patients with type 1 HPS, beneﬁts in reducing
morbidity pretransplantation have been described with coil
embolization [50].
5.PortopulmonaryHypertension
Portopulmonary hypertension [POPH] is deﬁned as pul-
monary arterial hypertension, with or without associated
liver disease. It was ﬁrst described by Mantz and Craige in
1951 [51]. The criteria for diagnosis is the presence of portal
hypertension, mean pulmonary arterial pressure more than
25mmHg at rest with a pulmonary capillary wedge pressure
less than 15mmHg, associated with the pulmonary vascular
resistance greater than 240dynes·sec·cm5.
Most patients of POPH have underlying cirrhosis but
it can also develop in noncirrhotic portal hypertension.
There is no direct correlation between severity of POPH and
etiology or severity of liver disease. POPH is found in 2 to
10% of cirrhotic patients [52–58]. In patients of refractory
ascites evaluated for TIPS an unusual high prevalence of
POPH of around 16% has been reported.
Male-to-femaleratiois1.1:1.POPHcanoccuratanyage
butmostcommonlypresentsinﬁfthdecadeoflife.Diagnosis
of portal hypertension precedes the diagnosis of POPH by
morethan4years.ThenaturalhistoryofPOPHhasnotbeen
fully elucidated. Spontaneous resolution of POPH has notInternational Journal of Hepatology 5
been reported. In pretransplant era median survival as low as
6 months was noted. The overall 3-to-5 year survival ranges
from 30 to 50% [59, 60].
Death occurs due to complications of liver disease and
complications related to POPH in equal proportion of cases.
Probability of death due to cardiopulmonary complications
ishighinthosewithlowcardiacindex.Anincreaseinplasma
brain natriuretic peptide (BNP) indicates stress on the right
ventricle. The diﬀerential diagnosis of dyspnea in a patient of
liver disease includes intrinsic cardiopulmonary conditions
such as chronic obstructive pulmonary disease, pneumonia,
pulmonaryembolism,congestiveheartfailure,valvularheart
disease, and conditions related to underlying liver disease
andportalhypertensionsuchasascites,hepatichydrothorax,
and muscle wasting [61, 62].
Arterial blood gas analysis shows hypocapnia, an
increased alveolar-arterial oxygen gradient and mild hypox-
emia. The X-ray chest may show cardiomegaly and promi-
nent main pulmonary artery.
POPH is graded according to the degree of elevation
of mean pulmonary arterial pressure. Mild POPH (mPAP
= 25–35mmHg) is not associated with increased operative
risk for liver transplantation and may not require medical
therapy. Moderate POPH (mPAP = 35–50mmHg) has
increasedoperativeriskforlivertransplantationandrequires
medicaltherapy.SeverePOPH(mPAP>50mmHg)hashigh
operative mortality and is managed with medical therapy
[52]. Histologically POPH has medial proliferation and
hypertrophy, plexiform arteriopathy, and in situ vascular
thrombosis of pulmonary vasculature. Cirrhosis is associ-
ated with hyperdynamic circulation with increased shearing
stress on pulmonary vasculature with resultant progressive
pulmonary vascular remodelling and thrombosis. There is
an imbalance between vasodilators and vasoconstrictors.
The associated bowel wall congestion due to splanchnic
vasodilatation leads to the release of endotoxins such as
endothelin-1 and thromboxane [58, 63, 64].
The most common symptom is exertional dyspnoea,
other symptoms like chest discomfort, fatigue, syncope, and
light headedness may also occur. The signs include elevated
jugular venous pressure, loud second pulmonic heart sound,
murmur of tricuspid regurgitation, and lower extremity
edema. Peripheral edema out of proportion to degree of
ascites in a cirrhotic patient, right ventricular dysfunction
secondary to pulmonary hypertension should be considered
[65, 66].
Transthoracic echocardiography is the recommended
screening test. It evaluates right heart function and estimates
the right ventricular systolic pressure. Echocardiography
excludes valvular heart disease and other causes of elevated
mPAP. Echocardiography may reveal changes due to raised
resistance to pulmonary ﬂow such as pulmonary valvular
insuﬃciency, right atrial dilatation, right ventricular hyper-
trophy and dilatation, interventricular septal thickening,
and paradoxical movement of septum. The correlation of
right ventricular pressure measured during echocardiogra-
phy and that from right heart catheterization is not good.
As echocardiography cannot estimate pulmonary vascular
resistance, approximately 30–40% of patients with estimated
right ventricular systolic pressure threshold can have normal
pulmonary vascular resistance during right heart catheteri-
zation and will not be diagnosed as POPH [67].
Another parameter measured during echocardiography
evaluation is pulmonary acceleration time. The value of
pulmonaryaccelerationtimegreaterthan100msecindicates
POPH. Echocardiography apart from the screening is also
helpful in followup of patients with POPH.
Right heart catheterization helps in estimation of mPAP,
pulmonary capillary wedge pressure, and cardiac output;
calculation of pulmonary and systemic vascular resistance.
Patients of liver disease have hyperdynamic circulation and
volume overload. Those with pulmonary capillary wedge
pressure greater than 15mmHg, the diagnosis of POPH may
be missed. The use of transpulmonary pressure gradient
helps in identifying patients with obstruction to ﬂow,
independent of pulmonary capillary wedge pressure. It is
calculated by subtracting pulmonary wedge pressure from
mean pulmonary arterial pressure [68]. Right ventricular
systolic pressure greater than 40mmHg or presence of right
ventricular abnormalities support further evaluation for
POPH. In all patients with echocardiographic abnormalities
suggestive of POPH, pulmonary artery catheterization is
performed to establish diagnosis and assess severity of
POPH.
Vasodilator testing using either inhaled nitric oxide or
intravenous epoprostenol during right heart catheterization
may be done. If the diagnosis of POPH is made, a decrease
in mPAP and PVR more than 20% from baseline without
decrease in cardiac output indicates reversible vasoconstric-
tion. Studies on long-term pharmacologic management of
POPH are lacking.
6. Medical Therapy
Supplemental oxygen is commenced if hypoxemia is present.
Diuretics are used for volume overload. If patients are on
B blockers, drugs are to be withdrawn. Treat the varices
withbandligation.Endothelinreceptorantagonist,Bosentan
is dual ETA and ETB receptor antagonist given orally. It
is started at the dose of 62.5mg twice daily and then
the dose can be increased to 125 to 250mg twice daily
[69]. Dose-dependant increase of liver enzymes is seen
because of inhibition of bile salt export protein. Treat-
ment with low-to-medium dose bosentan improves exercise
capacity and pulmonary hemodynamics. Phosphodiesterase
inhibitor, sildenaﬁl, inhibits the enzyme phosphodiesterase-
5. inhibition of degradation of NO promotes vasodilatation,
but may exacerbate portal hypertension and hyperdynamic
circulation [70].
Prostacyclin analogue, esoprostenol, is a potent systemic
and pulmonary vasodilator with antiplatelet aggregating
properties. It has a half-life of 3 to 5 minutes so requires
long-term continuous intravenous infusion [71]. It improves
pulmonary hemodynamic status. In some transplant centres
this may improve patient’s status for listing for liver trans-
plantation. Common side eﬀects include headache, ﬂushing,6 International Journal of Hepatology
diarrhoea,andhypotension[72].Morestableanaloguessuch
as iloprost and treprostinil are being investigated [73, 74].
Denovo POPH, transition from HPS to POPH and
recurrences of POPH in cases of graft failure have been
noted after LT. All candidates for liver transplantation should
undergo screening for portopulmonary hypertension by
echocardiography. If the echocardiography shows elevated
pulmonary arterial pressures, right heart catheterization is
performed to conﬁrm the diagnosis. The ideal medical
regimenremainstobedetermined.Althoughdrugtreatment
may lower pulmonary artery pressures in selected patients
so that liver transplantation can be safely done, morbidity
and mortality rates are higher in patients with moderate-
to-severe portopulmonary hypertension [75]. Moderate-to-
s e v e r eP O P Hw i t hm P A P> 50mmHg is contraindication to
LT. Liver transplantation is not the treatment of choice for
portopulmonary hypertension.
7. Hepatic Hydrothorax
Hepatic hydrothorax is deﬁned as the presence of pleural
ﬂuid (usually greater than 500cc) in a patient with cirrhosis
after ruling out primary cardiac or pulmonary disease. This
occurs in approximately 6–10% of patients with advanced
cirrhosis [76]. It is more commonly associated with alcohol-
induced liver disease and with the concomitant presence
of ascites. Regarding the side of involvement in hepatic
hydrothorax, 85% have been right sided, 13% left sided, and
2% bilateral [77].
8. Pathogenesis
Several mechanisms have been postulated for the devel-
opment of hepatic hydrothorax. The direct passage of
peritoneal ﬂuid via diaphragmatic defects appears to be the
most acceptable explanation. Lieberman et al. demonstrated
the defects by introducing CO2 into the peritoneal cavity of
patients with hepatic hydrothorax [78].
A pneumothorax indicative of a diaphragmatic defect
was seen in these patients on chest radiographs, taken within
48 hours. Intraperitoneal injection of methylene blue can be
used intraoperatively to localize the defect(s).
Several scintigraphic studies using intraperitoneal instil-
lation of 99mTc-human serum albumin or 99mTc-sulphor-
colloid have demonstrated radioactivity in the pleural cavity
minutes to hours after administration [79, 80].
The movement of radioisotope is unidirectional towards
the pleural cavity due to negative intrathoracic pressure
compared to increased intra-abdominal pressure. Micro-
scopic examinations of these defects have showed gaps in the
collagen bundles in the tendinous portion of the diaphragm.
In patients of ascites, there is increase in the intra-abdominal
pressure. This tends to stretch the diaphragm; thereby,
creating or enlarging these microscopic defects. The increase
in abdominal pressure results in herniation of peritoneum
through these gaps in the pleural cavity. This leads to the
formation of pleuroperitoneal blebs. These blebs tend to
rupture,creatingfreecommunicationbetweentheperitoneal
and pleural cavities. For certain unknown reasons the left
hemidiaphragm is more muscular and relatively resistant to
blebs formation.
9.ClinicalFeatures
It may simply be an incidental ﬁnding on a chest radiograph
performed for unrelated reasons in a patient of cirrhosis.
However, a small subset of cirrhotic patients may present
primarilywithpulmonarycomplaintsrelatedtohydrothorax
such as dyspnea, nonproductive cough, pleuritic chest pain,
or fatigue related to hypoxemia [81]. With large pleural eﬀu-
sions severe dyspnea and potential respiratory compromise
can occur.
There are several causes of pleural eﬀusion in general
and patients of cirrhosis can have any of those. In a study
on patients with end-stage liver disease patients with pleural
eﬀusions 30% of patients upon thoracentesis yielded a diag-
nosis other than hepatic hydrothorax including spontaneous
bacterial empyema (SBEM), tuberculosis, adenocarcinoma,
parapneumonic empyema, and undiagnosed exudates [82].
Hence both thoracentesis and paracentesis should be per-
formed to ascertain that both ﬂuids are similar in character
[83].
The composition of pleural ﬂuid from hepatic hydrotho-
rax, is similar to that of ascitic ﬂuid. However, ascitic
and pleural ﬂuid analysis may not be completely identical,
perhaps due to the greater eﬃcacy of water absorption by the
pleural surface. The cell count is usually low, and the total
protein, albumin, cholesterol, and total lipid levels may be
marginally higher in the pleural ﬂuid compared to ascitic
ﬂuid [84]. However, the serum-to-pleural ﬂuid albumin
gradient is usually greater than 1.1g/dL although, this has
not been studied extensively.
SBEM is the infection of a preexisting pleural eﬀusion
(hydrothorax) in a patient with cirrhosis. Its incidence is
around 15% (similar to the incidence reported for sponta-
neous bacterial peritonitis; SBP) in cirrhotic patients with
ascites [85].
Its pathogenesis is also similar to that of SBP. The
diagnosis of SBEM is made if the pleural ﬂuid (PF) cultures
are positive and a polymorphonuclear (PMN) count is
>250cells/μL. If culture is negative (and compatible clinical
course)thediagnosisismadewithapleuralﬂuidPMNcount
>500cells/μL and by excluding a parapneumonic infection
[86].
The microorganisms responsible for SBEM appear simi-
lar to that of SBP. Patient can present with local symptoms
such as dyspnea or pleuritic chest pain, or with systemic
symptoms such as fever, shock, or encephalopathy. Up to
40% of SBEM cases may not be associated with SBP. The
treatment of SBEM is similar to that of SBP [87]. Despite
treatment, mortality remains high at approximately 20%.
A l b u m i nt h e r a p ya t1 . 5g / k go nd a y1a n d1 . 0g / k go nd a y3
in the setting of SBEM may be considered although albumin
infusion has not been speciﬁcally studied in the setting of
hepatic hydrothorax and SBEM.International Journal of Hepatology 7
10.Diagnosis
This entity is usually suspected in a patient of cirrhosis
if patient presents with pulmonary symptoms or features
suggestive of pleural eﬀusion on examination or on routine
chest radiographs. A computerized tomographic (CT) scan
of the chest should be obtained to exclude any mediastinal,
pulmonary, or pleural pathology.
Moreover, detailed information of thediaphragm maybe
obtained with a CT scan or a magnetic resonance imaging,
permitting recognition of the small diaphragmatic defects
[88].
Thoracoscopy may also reveal the defects, but this
procedure is invasive and carries signiﬁcant morbidity in
patients with advanced liver disease and therefore is rarely
performed. Echocardiography may be indicated if there
is a suspicion of pericardial or a cardiac pathology. In
diﬃcult cases, speciﬁcally when ascites is not detected or
the hydrothorax is present on the left side; an intraperi-
toneal injection of [99Tcm] sulphur colloid or [99Tcm]-
human serum albumin may be helpful. Migration of the
radioisotopes from the peritoneal cavity into the pleural
space establishes a communication between both spaces and
conﬁrms that the ascites is the source of the eﬀusion [89,
90]. Conversely, failure of the marker to show up in the
pleural space indicates an alternate diagnosis for the pleural
eﬀusion. This test has been considered the gold standard for
identiﬁcation of hepatic hydrothorax due to its very high
speciﬁcity (up to 100%). However, its sensitivity remains
modest (approximately 71%). Fortunately, the sensitivity of
the test can be greatly improved (up to 100%) by performing
a thoracentesis prior to administration of radioisotopes in
order to reduce pleural pressure [91].
11. Treatment
The ﬁrst and most important aspect in the management of
all patients with cirrhosis and ascites or hepatic hydrothorax
is evaluation for candidacy for liver transplantation. Patients
of hepatic hydrothorax can be managed by dietary, pharma-
cologic, and radiological interventions. In selective patients
with refractory hydrothorax, surgical approaches aimed at
repairing the diaphragmatic defects responsible for pleural
ﬂuid accumulation can be considered.
12.DietandPharmacological Management
It is similar to the therapy of ascites. Achieving a negative
sodium balance is the primary goal of dietary and pharma-
cologic management. Dietary restriction of sodium intake to
2g/d (88mEq/d) is the simplest manner by which achieve a
negative sodium balance can be achieved [92].
However, most patients with ascites, and almost all
patientswithhepatichydrothoraxrequirediuretics(spirono-
lactone and/or furosemide) along with salt restriction. These
diuretics are maintained at a ratio of 10:4 (spironolactone
100mg: furosemide 40mg) to avoid dyselectrolytemia and
dosages are increased as needed to attain a goal of producing
renal excretion of at least 120mEq of sodium per day [93].
Patients not responding despite ﬂuid and sodium restric-
tion and use of maximal tolerable doses of diuretics are
considered to have refractory hydrothorax. Approximately
10% of patients either do not respond to diuretic therapy
or develop diuretic-induced complications that prevent the
use of high doses of these drugs. These patients should
be considered for orthotopic liver transplantation. Other
agents such as terlipressin, octreotide, and midodrine have
been used in small studies with moderate beneﬁt [94–96].
These agents will reduce splanchnic blood ﬂow and hence
decrease peritoneal and pleural ﬂuid accumulation. How-
ever, presently there is not enough evidence to recommend
routine use of these agents.
13. Thoracocentesis
It is a simple and relatively safe procedure which can be
performed in patients with dyspnea for immediate relief
of symptoms. In patients with dyspnea and both hepatic
hydrothorax and massive ascites, it is recommended to
drain the ascites prior to performing a thoracocentesis. It
is recommended that no more than 2 liters of ﬂuid should
be removed during the ﬁrst therapeutic thoracocentesis,
in order to minimize the risk of unilateral pulmonary
edema and/or hypotension [97]. The utility of concomitant
albumin infusion has not been established. However, given
the relatively small volume of ﬂuid removed at thoracentesis,
intravenous albumin to avoid circulatory dysfunction unlike
its routine use with large volume paracentesis seems unnec-
essary. The major risk of thoracocentesis is development of
pneumothorax. Usually diagnostic thoracocentesis carries a
low risk (1%) of pneumothorax, compared to therapeutic
thoracocentesis where the incidence is nearly 9% [82].
However,whenthoracocentesisisrequiredtoofrequently
(<every 2-3 weeks) in patients on maximal sodium restric-
tion and optimal diuretics, alternative treatment options
must be considered.
14. Radiologic Interventions:Transjugular
IntrahepaticPortosystemicShunts(TIPS)
It is a nonselective side-to-side portosystemic shunt which
decreases the sinusoidal hypertension that leads to ascites
formation—an essential step for pleural ﬂuid accumulation.
In a study by Gordon et al. 24 Child class B and C cirrhosis
patients following TIPS placement were evaluated. Fourteen
out of twenty-four (58.3%) had complete resolution of
symptoms following TIPS and did not require further
thoracocentesis. Another 5 (20.8%) required fewer number
of thoracentesis. But, despite this superior eﬃcacy, 6 patients
(25%) died of either postprocedure complications (1/6) or
liver failure (5/6), and 9 (37.5%) developed transient hepatic
encephalopathy [98]. Other groups have also showed symp-
tomatic improvement in many patients, but with associated
complications and did not improve the overall prognosis.
A recent study has shown that severity of liver dysfunction
is directly related to nonresponsiveness and higher one-year
mortality after TIPS placement for refractory HH [99].8 International Journal of Hepatology
Thus, it should be considered in selected patients who
reaccumulate their eﬀusions rapidly (despite medical treat-
ment) with a Child-Pugh score of less than 10, are younger
than 60 and do not have hepatic encephalopathy or severe
pulmonary hypertension.
15. Surgery
Pleurodesis: Falchuk et al. ﬁrst described the use of
tetracycline-induced pleurodesis in 2 patients with recurrent
hepatic hydrothorax. In that study, one patient remained
free of eﬀusion at 6-month followup while the other died
of variceal hemorrhage 3 weeks after the pleurodesis [100].
Chemical pleurodesis is not always successful and has a
modest risk of complications such as fever, chest pain,
empyema, incomplete reexpansion, pneumonia, and wound
infection. Hence pleurodesis by itself is rarely performed and
is reserved for patients in whom no other options exist.
Interestingly, the use of continuous positive airway pres-
sure (CPAP) appears eﬀective in keeping the pleural cavity
dry after chemical pleurodesis. The underlying mechanism
postulated is that CPAP will decrease the negative pleural
pressure and thus prevent the shift of ﬂuid form the
peritoneal to the pleural space [101]. Further studies are
needed before this can be routinely recommended.
Chest Tube Placement. It leads to massive ﬂuid shifts, pro-
tein, and electrolyte depletion. Hence, chest tube insertion
is considered a relative contraindication for the treatment of
hepatic hydrothorax [102].
Repair of Diaphragmatic Defects. Thoracoscopy to repair
diaphragmatic defects with/without sclerosing the pleural
membranes is a good alternative in patients with refractory
hepatichydrothoraxwhoarenotcandidatesforTIPS.Thora-
coscopy appears to be more likely to be eﬀective if diaphrag-
matic defects can be identiﬁed. In a study by Mouroux et
al. using video-assisted thoracoscopy (VATS) to close large
defects using sutures and biologic glue in combination with
talc pleurodesis in 8 patients. None of the patients (6/8) with
repaired defectsdeveloped recurrenthydrothorax despite the
recurrence of ascites [103]. Two other studies (15 and 41
patients each) showed almost 75% success rate with VATS-
assisted talc pleurodesis without resorting to diaphragmatic
repairs. Thus it may be considered a palliative alternative not
only to patients requiring frequent thoracentesis, but also an
alternative to TIPS [104, 105].
Peritoneovenous Shunts. A peritoneovenous shunt (Le Veen
shunt) to divert ascitic ﬂuid has been used in the past in
refractory cases. However, the shunt is rendered ineﬀective
over time as the intrathoracic pressure is lower than the
central venous pressure resulting in ﬂuid ﬂow towards the
pleural space [106]. Because of this reason and frequent
complicationsassociatedwithLeVeenshunt(infection,coag-
ulopathy,andbleedingincompromisedhost),thisprocedure
h a sb e c o m ea l m o s to b s o l e t e .
Liver Transplantation. It is the only option available when
all other therapies fail and is curative for most patients with
this complication. The short-term and long-term prognosis
in patients undergoing liver transplantation for refractory
hepatic hydrothorax appears similar to other groups [107].
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